Amgen Inc. (Nasdaq: AMGN) unveiled encouraging data from the CodeBreaK 101 clinical trial, showcasing the effectiveness of LUMAKRAS (sotorasib) plus chemotherapy (carboplatin and pemetrexed) in treating KRAS G12C-mutated advanced non-small cell lung cancer. In first-line patients, the treatment achieved a remarkable 65% objective response rate. Safety profiles were consistent with previous findings, with no fatal adverse events reported.

Based on these results, Amgen is launching a Phase 3 study for LUMAKRAS in first-line treatment, expected to begin by the end of 2023.

On Friday, $AMGN closed at $259.43, up 1.98%.

In other news, Gilead Sciences, Inc. (Nasdaq: GILD) has unveiled promising early data from the Phase 2 EVOKE-02 study, evaluating Trodelvy (sacituzumab govitecan-hziy) in combination with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) in previously untreated advanced non-small cell lung cancer (NSCLC). Results from two cohorts show significant promise: Cohort A achieved a 69% objective response rate (ORR), while Cohort B achieved a 44% ORR. Across both cohorts, the ORR was 56%, with an 88% response rate at six months. The safety profile remains consistent with known data.

Gilead entered into collaboration with Merck to explore this combination in Phase 2 and Phase 3 studies. It's important to note that these treatments are investigational, and regulatory approval is pending.

On Friday, $GILD closed at $76.00, marking a gain of $2.06 (2.79%), while $MRK closed at $109.05, up $1.11 (1.03%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)